BioMAN Summit - November 2-3, 2016

Transforming Manufacturing to
Supply Biologic Medicines for Today and Tomorrow

The Massachusetts Institute of Technology’s Center for Biomedical Innovation (CBI) BioMAN Program will host a two-day Summit on the transformation of biologics manufacturing to meet the challenges of supplying existing and revolutionary new products to changing markets.

The 2016 BioMAN Summit will bring together thought leaders from industry, academia, and government bodies for a series of invited presentations and a panel discussion that will:

Examine how increasing numbers of disease targets, expanding patient populations, and evolving therapeutic modalities will impact biomanufacturing operations;
Discuss lessons learned from new biopharmaceutical manufacturing facilities designed to meet future demands in scale and scope of therapies;
Explore innovative emerging technologies that can meet the manufacturing challenges associated with new biotherapeutic modalities;
Identify technology and policy gaps that stakeholders can collaboratively address in order to enable the transformation of biologics manufacturing.

– Keynote Speakers –

Jeffrey C. Baker, Deputy Director, Office of Biotechnology Products, CDER, FDA

Jorg Thommes, Senior Vice President, Engineering & Technology, Biogen

– Confirmed Speakers –

John Aunins, Executive Vice President of Bioprocess & Manufacturing and Chief Technology Officer, Seres Therapeutics

David Berry, General Partner, Flagship Ventures

James Bouressa, Senior Director, Clinical Manufacturing, Pfizer

Stuart Bussell, Senior Director, Process Development, Sutro Biopharma

Jie Chen, Vice President, CMC Operations, WuXi Biologics

Eliana Clark, Vice President, Manufacturing Sciences, Biogen

Charles L. Cooney, Professor Emeritus, Department of Chemical Engineering; Faculty Director Emeritus, Deshpande Center for Technological Innovation, MIT

Parrish M. Galliher, Chief Technology Officer, Upstream, GE Healthcare Life Sciences

Shekar Ganesa, Executive Director, Process Development, Amgen

Hugh A. Haydon, President, Kentucky BioProcessing

Gregory Hiller, Associate Research Fellow, Culture Process Development, Pfizer

Nathan C. Ihle, Vice President, CMC Strategy & Management, Seattle Genetics

Avak Kahvejian, Co-founder and Chief Executive Officer, Rubius Therapeutics

Stephen Kennedy, Chief Technology Officer, Histogenics

Konstantin Konstantinov, Senior Vice President, Manufacturing & Process Sciences, Codiak BioSciences

René Labatut, Vice President, Technology Innovation, Sanofi Pasteur

J. Christopher Love, Associate Professor, Department of Chemical Engineering, MIT

Aura Mackenzie, Senior Principal, Global Pricing and Product Strategy, Precision for Value

Samantha Maragh, Leader, Genome Editing Program, NIST

Travis A. McCready, President & Chief Executive Officer, Massachusetts Life Sciences Center

PJ Millan, Head of Process Automation, R&D Platform Technology & Science, GlaxoSmithKline

Peter Nguyen, Technology Development Fellow, Laboratory of James Collins, Wyss Institute of Biologically Inspired Engineering, Harvard University

Rajeev Ram, Professor, Department of Electrical Engineering and Computer Science, MIT

Rahul Singhvi, Senior Vice President and Chief Operating Officer, Global Vaccine Business Unit, Takeda Pharmaceuticals International

Anthony Sinskey, Professor, Department of Biology; Faculty Director, CBI, MIT

Ariel Dora Stern, Assistant Professor of Business Administration, Harvard Business School

Christopher Stevens, Senior Director, Operations, Planning, and Strategy - Biopharm and Cell & Gene Therapy, GlaxoSmithKline

Krystyn J. Van Vliet, Professor, Department of Materials Science and Engineering and Department of Biological Engineering; Director of Manufacturing Innovation, MIT Innovation Initiative, MIT

J. Fraser Wright, Co-founder and Chief Technology Officer, Spark Therapeutics